Inventor
Michael Prime
Inventor
Abingdon, GB
Overview
Patents· 20 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds33%
A61KPreparations for medical, dental or toiletry purposes23%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations21%
C07CAcyclic or carbocyclic compounds5%
C07HSugars5%
A61BDiagnosis3%
C07BGeneral methods of organic chemistry3%
Y02ATechnologies for adaptation to climate change3%
C04D2%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms2%
PatentTitleYear
11,104,691Probes for imaging huntingtin protein202111,059,836Probes for imaging huntingtin protein202110,907,197Probes for imaging huntingtin protein202110,765,764Probes for imaging huntingtin protein202010,501,433Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof201910,479,802Probes for imaging huntingtin protein201910,442,782Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof201910,428,054Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof201910,137,211Probes for imaging Huntingtin protein20189,981,918Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof20189,938,252Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof20189,884,853'Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof'20189,822,058'Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof'20179,649,310'Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof'20179,428,464'Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof'20169,260,422'Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof'20168,946,197'Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof'20158,889,716'Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof'20147,939,532'Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents'20117,749,994'Pentacyclic kinase inhibitors'2010Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2010Based in Abington, GB· patent location history
2011Based in Oxon, GB· patent location history
2014–2021Patents assigned to CHDI FOUNDATION INC (18)· patent assignee history
2014–2018Patents assigned to COURTNEY STEPHEN MARTIN (5)· patent assignee history
2014–2018Patents assigned to DOMINGUEZ CELIA (5)· patent assignee history
2014–2018Patents assigned to PRIME MICHAEL (5)· patent assignee history
2014–2019Based in Abingdon, GB· patent location history
2015–2018Based in Oxfordshire, GB· patent location history
2016–2018Patents assigned to BROWN CHRISTOPHER JOHN (3)· patent assignee history
2018–2021Based in Swindon, GB· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| CHDI FOUNDATION INC | 18 | 2014–2021 |
| COURTNEY STEPHEN MARTIN | 5 | 2014–2018 |
| DOMINGUEZ CELIA | 5 | 2014–2018 |
| PRIME MICHAELself | 5 | 2014–2018 |
| BROWN CHRISTOPHER JOHN | 3 | 2016–2018 |
Locations
| Location | Patents | Span |
|---|---|---|
| Abingdon, GB | 7 | 2014–2019 |
| Swindon, GB | 6 | 2018–2021 |
| Oxfordshire, GB | 5 | 2015–2018 |
| Oxon, GB | 1 | 2011 |
| Abington, GB | 1 | 2010 |